Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By sjmartinez • August 16, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC. PMID: 37364283.

Tags: COPD, dual PDE3 and PDE4 inhibitor, ensifentrine, nebulized therapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Mirtazapine reduces hypothetical methamphetamine demand in humans

Rush CR, Santos GM, McMahan VM, Fraser A, Clark J, Luna Marti X, Walker JE, Shoptaw S, Coffin PO. Mirtazapine reduces hypothetical methamphetamine demand in[...]

SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma

Powles TB, Grande E, Alimohamed N, Oliveira N, Sridhar SS, Drakaki A, Kanesvaran R, Loriot Y, Necchi A, Franco S, Jiang D, Apolinario K, Zhang[...]

Experiences and perspectives of patients and their caregivers on gastrointestinal symptoms in peritoneal dialysis: Workshop report

Hayat A, Johnson DW, Manera K, Viecelli AK, Wilkie M, Shen J, Wang AY, Htay H, Jaure A, Cho Y, Walker R. Experiences and perspectives[...]